At the news
? BULLISHIMPACT 8/10 8-K filed Mar 12, 2026 at 06:00 ET
Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing robust microdystrophin expression and biomarker improvements in Duchenne muscular dystrophy patients. The company also confirmed FDA alignment on the Phase 3 IMPACT DUCHENNE trial design, with dosing expected to begin in Q1 2026.
- SGT-003 showed 60% mean microdystrophin expression by western blot at Day 90 (n=19), increasing to 91% at Day 360 (n=3)
- Mean vector copies per nucleus were 11 at Day 90 and 12 at Day 360, indicating stable transduction
- Key biomarkers showed significant improvement: 38% mean reduction in serum creatine kinase (CK) at Day 90, 44% reduction in eMHC-positive fibers suggesting disruption of degeneration-regeneration cycle
- FDA has agreed the Phase 3 IMPACT DUCHENNE trial design is reasonable, with dosing expected in Q1 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access